Working Group 3 Report

March 04 2015
Pharmacosurveillance gaps and opportunities: phenotype definitions, EMRs, resource needs

- R. Davis (chair)
- J. Denny
- G. Ginsburg
- B. Iglesias
- S. Iyasu
- L. La Grenade
- T. Manolio
- M. Mockenhaupt
- Z. Mohamed
- E. Phillips
- S. Pinheiro (chair)
- D. Roden
- C. Sung
- W. Suwankensawong
- L. Wheatley
- K. Wiley
- M. Wiliams
Key gaps in pharmacosurveillance

Main challenge: difficulties in case ascertainment
- Standardized case definition
- Minimum set of variables (differentiate cases from non-cases)
- Generalizable to use on common data models (and/or with other EMRs)
- Needs ability to dig deeper; e.g. medical chart validation of phenotype, drug culprits, timing of exposure, risk factors

Next Steps
- Evaluate different case definitions used by others; e.g. EuroSCAR, RegiSCAR, ITCH, and other SJS projects
- Iterative process among researchers and clinicians to arrive at a common definition

Synthesis
- Active surveillance with real-time data collection is fundamentally different from retrospectively collected data with case validation
- Set of items to satisfy both collection efforts
Capabilities of developing active monitoring in U.S.

- May need multiple strategies that include use of both prospective and retrospective data collection

- Prospective collection for complete case ascertainment and pharmacogenomics studies
  - Burn units seems a promising approach, focusing on a few large areas/cities may be helpful.

- Use of existing large databases for active surveillance?
  - Capabilities being developed in some databases for pharmacogenomics studies
  - Needs ability to identify cases reliably, needs ability to conduct case validation (blinded to exposure status), needs standardized processes for collecting genetic data across disparate sites
    - eMERGE has had success in shepherding this process successfully
Estimating rates of SJS/TEN

• How much of a priority is it to understand rates
  – Trends over time may not be helpful
  – Relevant for cost-effective studies, to estimate burden of disease, product-specific rates

• Needs nearly complete capture of cases and ability to identify cases
  – If capability is developed, consider assessing product-specific rates, race-specific
  – limit to incidence medication use
Epidemiology of disease progression

• Current poor understanding of factors associated with disease progression
• Long-term outcomes of SJS/TEN not well understood.

Next steps
• Consider use of ScoreTEN
  – 7 point score used for prognosis, calculated on day 3 of disease
  – Limitations is that data not always collected on day 3; e.g. lab values, and some characteristics such as lung involvement are not considered
• Consider future studies to address the range and extent of outcomes and disabilities
Other Items

• Large scale collaborations in US might be stimulated by concerted efforts to deposit data into public databases such as ClinVar (or others such as dbGAP)

• Challenges with current screening recommendations; i.e. low PPV of haplotypes